Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01352520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01352520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Brentuximab Vedotin (SGN-35) at Dose of 1.8 mg/kg IV Every 3 Weeks in Patients With CD30-positive Lymphoproliferative Disorders (Cutaneous Anaplastic Large T-cell Lymphoma (ALCL), Mycosis Fungoides, and Extensive Lymphomatoid Papulosis (LyP)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2011
Completion date
January 31, 2028
Enrollment
79 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd-30 positive anaplastic large t-cell cutaneous lymphoma, cutaneous lymphomas, hematologic disorder, lymphoma, lymphoma, primary cutaneous anaplastic large cell, lymphomatoid papulosis, mycosis fungoides, skin lymphoma